Who will challenge Gilead in hepatitis C battle?
This article was originally published in Scrip
Executive Summary
At one point in Vertex Pharmaceuticals’ quarterly call with analysts this week, company executives were asked if they were truly committed to developing a new treatment for hepatitis C.